The MAKE Biomarker Discovery for Enhancing anTidepressant Treatment Effect and Response (MAKE BETTER) Study: Design and Methodology

키워드

참고문헌 (52)

1. World Health Organization, "The Global Burden of Disease: 2004 Update" (2008), WHO Press
2. Chapter 2: Burden of mental and behavioral disorders. In the World health report 2001-Mental health: New Understanding, New hope Impact of disorders, "World Health Organization", ~
3. Al-Harbi KS, "Treatment-resistant depression: therapeutic trends, challenges, and future directions", Patient Prefer Adherence, 6, pp.369~388 (2012)
4. Jenkins E, "Approaches to understanding and addressing treatment-resistant depression: a scoping review", Depress Res Treat, 2012, pp.469680~ (2012)
5. Trivedi MH, "Medication augmentation after the failure of SSRIs for depression", New Engl J Med, 354, pp.1243~1252 (2006)[DOI]
6. Berlim MT, "Current trends in the assessment and somatic treatment of resistant", refractory major depression: an overview, 2008, pp.40, 149~159
7. Steimer W, "Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy", Clin Chim Acta, 308, pp.33~41 (2001)[DOI]
8. McMahon FJ, "Clinically useful genetic markers of antidepressant response: how do we get there from here?", Am J Psychiatry, 172, pp.697~699 (2015)[DOI]
9. Kato M, "Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder", Mol Psychiatry, 15, pp.473~500 (2010)[DOI]
10. Ising M, "A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression", Arch Gen Psychiatry, 66, pp.966~975 (2009)[DOI]
11. Garriock HA, "A genomewide association study of citalopram response in major depressive disorder", Biol Psychiatry, 67, pp.133~138 (2010)[DOI]
12. Uher R, "Genome-wide pharmacogenetics of antidepressant response in the GENDEP project", Am J Psychiatry, 167, pp.555~564 (2010)[DOI]
13. Myung W, "A genomewide association study of antidepressant response in Koreans", Transl Psychiatry, 5, pp.e633~ (2015)[DOI]
14. Biernacka JM, "The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response", Transl Psychiatry, 5, pp.e553~ (2015)[DOI]
15. Sasayama D, "Possible association of CUX1 gene polymorphisms with antidepressant response in major depressive disorder", Pharmacogenomics J, 13, pp.354~358 (2013)[DOI]
16. GENDEP Investigators, "Common genetic variation and antidepressant efficacy in major depressive disorder: A meta-analysis of three genome-wide pharmacogenetic studies", Am J Psychiatry, 170, pp.207~217 (2013)[DOI]
17. Holsboer F, "How can we realize the promise of personalized antidepressant medicines?", Nat Rev Neurosci, 9, pp.638~646 (2008)[DOI]
18. Tammiste A, "Whole exome sequencing identifies a polymorphism in the BMP5 gene associated with SSRI treatment response in major depression", J Psychopharmacol, 27, pp.915~920 (2013)[DOI]
19. Brunoni AR, "A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression", Int J Neuropsychopharmacol, 11, pp.1169~1180 (2008)[DOI]
20. Fernandes BS, "Decreased peripheral brain-derived neurotrophic factor levels are a biomarker of disease activity in major psychiatric disorders: a comparative metaanalysis", Mol Psychiatry, 19, pp.750~751 (2014)[DOI]
21. Polyakova M, "BDNF as a biomarker for successful treatment of mood disorders: a systematic & quantitative meta-analysis", J Affect Disord, 174, pp.432~440 (2015)[DOI]
22. Wolkowitz OM, "Serum BDNF levels before treatment predict SSRI response in depression", Prog Neuropsychopharmacol Biol Psychiatry, 35, pp.1623~1630 (2011)[DOI]
23. Vreeburg SA, "Associations between sociodemographic, sampling and health factors and various salivary cortisol indicators in a large sample without psychopathology", Psychoneuroendocrinology, 34, pp.1109~1120 (2009)[DOI]
24. Lok A, "Longitudinal hypothalamic-pituitary-adrenal axis trait and state effects in recurrent depression", Psychoneuroendocrinology, 37, pp.892~902 (2012)[DOI]
25. Ruhe HG, "Longitudinal effects of the SSRI paroxetine on salivary cortisol in Major Depressive Disorder", Psychoneuroendocrinology, 52, pp.261~271 (2015)[DOI]
26. Hardeveld F, "Increased cortisol awakening response was associated withtime to recurrence of major depressive disorder", Psychoneuroendocrinology, 50, pp.62~71 (2014)[DOI]
27. Binder E, "The role of FKBP5: a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders", Psychoneuroendocrinology, 34(Suppl 1), pp.S186~S195 (2009)[DOI]
28. Bockting CL, "Lower cortisol levels predict recurrence in remitted patients with recurrent depression: a 5.5 year prospective study", Psychiatry Res, 200, pp.281~287 (2012)[DOI]
29. Howren MB, "Associations of depression with Creactive protein, IL-1, and IL-6: a meta-analysis", Psychosom Med, 71, pp.171~186 (2009)[DOI]
30. Valkanova V, "CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies", J Affect Disord, 150, pp.736~744 (2013)[DOI]
31. Hannestad J, "The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a metaanalysis", Neuropsychopharmacology, 36, pp.2452~2459 (2011)[DOI]
32. Strawbridge R, "Inflammation and clinical response to treatment in depression: a meta-analysis", Eur Neuropsychopharmacol, 25, pp.1532~1543 (2015)[DOI]
33. Kautzky A, "A new prediction model for evaluating treatment-resistant depression", J Clin Psychiatry, 78, pp.215~222 (2017)[DOI]
34. Garcia-Gonzalez J, "Pharmacogenetics of antidepressant response: a polygenic approach", Prog Neuropsychopharmacol Biol Psychiatry, 75, pp.128~134 (2017)[DOI]
35. Tansey KE, "Contribution of common genetic variants to antidepressant response", Biol Psychiatry, 73, pp.679~682 (2013)[DOI]
36. Sheehan DV, "The mini-international neuropsychiatric interview (M.I.N.I): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10", J Clin Psychiatry, 59(Suppl 20), pp.S22~S33 (1998)
37. Kennedy SH, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments", Can J Psychiatry, 61, pp.540~560 (2016)[DOI]
38. "Treating Major Depressive Disorder; Practice Guideline for the treatment of patients with major depressive disorder, Third Ed"[URL]
39. Hamilton M, "A rating scale for depression", J Neurol Neurosurg Psychiatry, 23, pp.56~62 (1960)[DOI]
40. Rammstedt B, "Measuring personality in one minute or less: A 10-item short version of the Big Five Inventory in English and German", J Res Pers, 41, pp.203~212 (2007)[DOI]
41. Zimet, "The multidimensional scale of perceived social support", J Pers Assess, 52, pp.30~41 (1988)[DOI]
42. Lee YH, "Relations Between Attributional Style, Life Events, Event Attribution, Hopelessness and Depression", pp.1993
43. Cohen S, "A Global Measure of Perceived Stress", J Health Soc Behav, 24, pp.385~396 (1983)[DOI]
44. Connor KM, "Development of a new resilience scale: the Connor-Davidson Resilience Scale (CD-RISC)", Depress Anxiety, 18, pp.76~82 (2003)[DOI]
45. Guy W, "ECDEU Assessment Manual for Psychopharmacology" (1976), National Institute of Mental Health
46. Zigmond AS, "The Hospital Anxiety and Depression Scale", Acta Psychiatr Scand, 67, pp.361~370 (1983)[DOI]
47. Salter K, "The assessment of poststroke depression", Top Stroke Rehabil, 14, pp.1~24 (2007)
48. American Psychiatric Association, "Diagnostic and Statistical Manual of Mental Disorders, 4th Ed" (1994), American Psychiatric Press Inc
49. Sheehan DV, "The Anxiety Disease" (1983), Charles Scribner Sons
50. Overall JE, "The brief psychiatric rating scale", Psychol Rep, 10, pp.799~812 (1962)[DOI]
51. Endicott J, "A diagnostic interview: the Schedule for affective disorders and schizophrenia", Arch Gen Psychiatry, 35, pp.837~844 (1978)[DOI]
52. Rabin R, "EQ-5D: a measure of health status from the EuroQol Group", Ann Med, 33, pp.337~343 (2001)[DOI]

관련 논문AI추천